Research

An international analysis.

Key lessons, challenges, and opportunities for the future.

Corporate Power, Public Power, and the Future of Prescription Drug Policy in the United States

At nearly $20 billion in sales in 2018, adalimumab (Humira) dominates the worldwide biologic market, with more than twice the annual sales of the second-highest selling drug, lenalidomide (Revlimid).

International Prices and Therapeutic Equivalency

There have been a lot of innovations in Medicare over the last decade or so, with the intent of improving the program's value. There have been some successes, but there is still a lot to be done.

More than half of new drugs entering the German healthcare system have failed to demonstrate any added benefit.

Opioid deaths in the United States have soared over the last two decades, driving a wave of litigation against drugmakers and distributors.

A bill introduced last year in the US House of Representatives that would reward manufacturers of certain novel antibiotics with transferrable market exclusivity vouchers could end up costing public and private payers $4.5 billion over 10 years.

And taxpayers are footing most of the bill.

The US federal government believes the opioid crisis has led to 400,000 Americans losing their lives. 

KFF analyzes changes in list prices for drugs covered by Medicare Part D in recent years compared to changes in the rate of inflation.

Annual Estimates and Projections for 2015 through 2019

There are numerous challenging trade-offs when choosing an approach to health care reform.

The average launch prices for new brand-name drugs have skyrocketed over the past decade, according to an analysis from drug research firm 46brooklyn.